UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-12, Vol.9 (12), p.4381-4392.e4

2021

Volltextzugriff (PDF)

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

Allergy (Copenhagen), 2022-06, Vol.77 (6), p.1786-1796

2022

Volltextzugriff (PDF)

Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study

Thorax, 2023-07, Vol.78 (7), p.643-652

2023

Volltextzugriff (PDF)

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma

The European respiratory journal, 2021-12, Vol.58 (6), p.2100413

2021

Volltextzugriff (PDF)

Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis

Allergy (Copenhagen), 2022-01, Vol.77 (1), p.150-161

2022

Volltextzugriff (PDF)

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

Respiratory research, 2015-08, Vol.16 (1), p.92-92, Article 92

2015

Volltextzugriff (PDF)

Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-06, Vol.10 (6), p.1534-1544.e4

2022

Volltextzugriff (PDF)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol

Respiratory research, 2017-05, Vol.18 (1), p.106-106, Article 106

2017

Volltextzugriff (PDF)

Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers

Respiratory research, 2021-10, Vol.22 (1), p.272-272, Article 272

2021

Volltextzugriff (PDF)

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies

Respiratory research, 2016-05, Vol.17 (1), p.61, Article 61

2016

Volltextzugriff (PDF)

Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study

Chronic obstructive pulmonary disease, 2013-08, Vol.10 (4), p.511-522

2013

Volltextzugriff (PDF)

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Dermatology and therapy, 2024-08, Vol.14 (8), p.2181-2193

2024

Volltextzugriff (PDF)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial

ERJ open research, 2019-07, Vol.5 (3), p.9

2019

Volltextzugriff (PDF)

Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD

Respiratory medicine, 2014-02, Vol.108 (2), p.358-365

2014

Volltextzugriff (PDF)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis

International journal of chronic obstructive pulmonary disease, 2016-01, Vol.11 (1), p.2041-2053

2016

Volltextzugriff (PDF)

ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients

Clinical drug investigation, 2013-12, Vol.33 (12), p.893-904

2013

Volltextzugriff (PDF)

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

The lancet respiratory medicine, 2022-01, Vol.10 (1), p.47-58

2022

Volltextzugriff (PDF)

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial

Clinical therapeutics, 2010-09, Vol.32 (10), p.1798-1812

2010

Volltextzugriff (PDF)

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

British journal of dermatology (1951), 2023-05, Vol.188 (6), p.740-748

2023

Volltextzugriff (PDF)

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD

NPJ primary care respiratory medicine, 2017-02, Vol.27 (1), p.13-13, Article 13

2017

Volltextzugriff (PDF)

Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations

ERJ open research, 2020-10, Vol.6 (4), p.246

2020

Volltextzugriff (PDF)

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Respiratory research, 2020-10, Vol.21 (1), p.266-266, Article 266

2020

Volltextzugriff (PDF)

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

Respiratory research, 2020-10, Vol.21 (1), p.1-264, Article 264

2020

Volltextzugriff (PDF)

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

The European respiratory journal, 2024-07, Vol.64 (1), p.2301521

2024

Volltextzugriff (PDF)

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN

The European respiratory journal, 2014-11, Vol.44 (5), p.1156-1165

2014

Volltextzugriff (PDF)

1 – 25 von 563

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(500)
Mit Volltextzugriff
(498)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma

Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol

Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies

Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial

Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis

ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD

Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN

Suchergebnisse filtern